BIONTTECH
Sensor Technology for explosive detection. Based on Georgia Tech Research.
Similar Organizations
S3I
S3I, LLC, is a technology leader specializing in biological threat detection. The company will be part of ICx BioSystems.
Founder
More informations about "BionTTech"
BioNTech - Wikipedia
BioNTech was founded in 2008 based on research by UÄŸur Åžahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich …See details»
From Discovery to Delivery – Meet our Senior Team - BioNTech
Having joined BioNTech in 2019, the year in which BioNTech went public, Lisa has since played a key role in building, expanding and professionalizing the finance organization. She has been …See details»
BioNTech | Our mission: basic research in mRNA technology and …
BioNTech’s portfolio contains more than 25 product candidates in clinical trials. In pursuit of changing the treatment paradigm with individualized cancer therapies, our pipeline …See details»
BioNTech Org Chart + Executive Team - The Official Board
Mar 28, 2025 Organizational Chart of BioNTech. BioNTech Org Chart www.biontech.de. has 41 executives and 3 subsidiaries +49 613 190 840; Add an executive. BioNTech (BNTX) News . …See details»
Management Report on the Group and the Company for the 2020 …
May 19, 2021 BioNTech SE was founded in 2008 as a spin-off from the Johannes Gutenberg University Mainz. The underlying broad technology and patent portfolio was built up over a …See details»
BioNTech US
BioNTech US originated as Neon Therapeutics, which was acquired by BioNTech SE in 2020 to combine neoantigen expertise in the field of cancer medicine and immunology by leveraging the highly complementary capabilities and …See details»
Overview - BioNTech
BioNTech SE. An der Goldgrube 12. 55131 Mainz, Germany. T: +49 6131 9084-0. F: +49 6131 9084-2121. [email protected]. Footer Social Links. Twitter. Linkedin. Company. About …See details»
BioNTech - The Org
BioNTech was founded in 2008 on the understanding that every cancer patient’s treatment should be individualized. Their vision is to provide patient-specific immunotherapies worldwide. …See details»
BioNTech Announces Appointment of Ramón Zapata to
1 day ago He strengthened BioNTech’s global finance organization and processes and contributed to the Company’s financial stability while increasing operational efficiency. Today, …See details»
BioNTech SE - Devex
Learn more about BioNTech SE's jobs, projects, latest news, contact information and geographical presence. BioNTech was founded in 2008 on the understanding that every …See details»
BioNTech - Crunchbase Company Profile & Funding
BioNTech creates protein-based therapeutics, including antibodies and antibody-drug conjugates, to address various tumor types and bacterial infections. Small Molecule Immunomodulators …See details»
BioNTech | Collaborators
In addition, BioNTech and Ryvu jointly undertake drug discovery and research projects to develop multiple small molecule programs directed at exclusive targets selected by BioNTech, primarily focused on immune modulation within …See details»
BNTX Combined Management Report 2022 - BioNTech
BioNTech SE is the parent company of the BioNTech Group and is responsible for the management and development of the Group. BioNTech SE has its registered office in Mainz, …See details»
BioNTech SE Company Profile - Overview - GlobalData
BioNTech SE (BioNTech) is a biotechnology company that develops immunotherapies for cancer and infectious diseases. The company's primary activities involve harnessing the immune …See details»
BioNTech Strives to Become Commercial ‘Powerhouse’ While
Jan 16, 2025 BioNTech partnered with Pfizer to produce the COVID-19 vaccine during the pandemic, a relationship that is ongoing. ... I had to build a team. I had to build the …See details»
BioNTech Announces Appointment of Ramón Zapata to …
1 day ago He will join BioNTech from Novartis AG’s global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, …See details»
BioNTech Appoints Novartis Executive As Finance Chief ... - Benzinga
1 day ago BioNTech reported Q1 revenue of $192.23 million, surpassing the consensus of $177.40 million. Cash and investments totaled 15.85 billion euros as of March 31, 2025. Don’t …See details»
BioNTech Clinical Trials | Advancing Health Through Innovation
At BioNTech, we are committed to improving the health of people worldwide by developing novel medicines to address cancer, infectious diseases and other serious diseases. Clinical trials are …See details»
BioNTech | Global Health Commitment
BioNTech aspires to translate science into survival by addressing pressing health challenges we face as a global society. Based on our mRNA technology and our experience in the field of …See details»
Novartis executive Ramon Zapata-Gomez to join BioNTech as CFO
18 hours ago Germany: BioNTech SE has announced that the Supervisory Board has appointed Ramon Zapata-Gomez to the Management Board as Chief Financial Officer (CFO) effective …See details»